Trial · NCT00923481
Adverse events95
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 95
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 22 | 37 | 57 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 23 | 37 | 66 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 29 | 37 | 77 |
| other | Alkaline phosphatase | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 17 | 37 | 32 |
| other | Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Ascites (non-malignant) | Gastrointestinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Atelectasis | Respiratory, thoracic and mediastinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Bicarbonate, serum low | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 2 | 37 | 2 |
| other | Bilirubin (hyperbilirubinemia) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 13 | 37 | 29 |
| other | Bruising (in absence of Grade 3 or 4 thrombocytopenia) | Injury, poisoning and procedural complications | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Burn | Injury, poisoning and procedural complications | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | CPK (creatine phosphokinase) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 7 | 37 | 15 |
| other | Calcium, serum-high (hypercalcemia) | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 10 | 37 | 19 |
| other | Calcium, serum-low (hypocalcemia) | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 5 | 37 | 7 |
| other | Cholesterol, serum-high (hypercholesteremia) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 2 | 37 | 3 |
| other | Constipation | Gastrointestinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 2 | 37 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 6 | 37 | 7 |
| other | Creatinine | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 4 | 37 | 8 |
| other | Dehydration | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 2 | 37 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00923481/events